HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Regunera

FDA

Regulatory intelligence
FDAsafety guidance83% confidence

Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers

Source: FDA

Why This Matters

Why this matters: illustrates how regulators handled a comparable safety guidance decision relevant to Sandoz.

Regulatory Analysis

Certain AIC units require hardware updates to address potential safety concerns that could lead to a delay or loss of hemodynamic support.

Supporting Context

Therapeutic area
Cardiovascular · Anticoagulant
Sub-indication
General

Related signal: Sandoz Issues Class 4 Medicines Defect Notification for Apixaban Tablets

Source

View source document

Related Signal

Open signal — Sandoz Issues Class 4 Medicines Defect Notification for Apixaban Tablets
PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.